This study is a single-center, prospective, group-controlled clinical trial, aiming to clarify the relationship between the depth of dissection and scar formation in the treatment of early gastric cancer by ESD, and to provide high-quality evidence-based medicine for the treatment of early gastric cancer.
Patients older than 18 years old and younger than 75 years old.
Early gastric cancer (T1a stage) diagnosed by gastroscopy or ultrasonography, differentiated and no ulcer; or early gastric cancer (T1a stage), differentiated with ulcer, lesion diameter <3cm; or early gastric cancer (T1a stage), undifferentiated and No ulcer, lesion diameter <2cm.
Pathological diagnosis of gastric cancer.
No further treatment is required.
Those who did not comply with the test requirements, obviously violated this protocol, or switched to other protocols in the middle of treatment.
Advanced gastric cancer; or undifferentiated gastric cancer lesions > 2 cm in diameter; or differentiated gastric cancer with ulcer lesions > 3 cm in diameter.
Coagulation disorders.
Serious heart, liver, kidney and other diseases, can not tolerate ESD treatment.